Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    5
    ...
ATC Name B/G Ingredients Dosage Form Price
C10AA05 LIPONORM G Atorvastatin (calcium) - 40mg 40mg Tablet, film coated 1,491,665 L.L
L02BG04 LETROZOLE ARROW G Letrozole - 2.5mg 2.5mg Tablet, film coated 2,402,790 L.L
C10AA05 LORVAST G Atorvastatin (calcium) - 40mg 40mg Tablet, film coated 1,253,805 L.L
L02BG04 LETROZOLE ARROW LAB G Letrozole - 2.5mg 2.5mg Tablet, coated 2,000,981 L.L
G04BE08 LINK G Tadalafil - 20mg 20mg Tablet, film coated 1,374,751 L.L
L02BG04 LETROZOLE BIOGARAN G Letrozole - 2.5mg 2.5mg Tablet, coated 2,402,790 L.L
G04BE08 LINK G Tadalafil - 20mg 20mg Tablet, film coated 369,557 L.L
L02BG04 LETROZOLE NEAPOLIS G Letrozole - 2.5mg 2.5mg Tablet, film coated 2,060,111 L.L
J01MA02 LADININ G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 595,060 L.L
R06AE09 LEVOTREX G Levocetirizine dihydrochloride - 5mg 5mg Tablet, film coated 447,948 L.L
R06AE09 LIVIDA G Levocetirizine dihydrochloride - 5mg 5mg Tablet, film coated 447,948 L.L
N03AX14 LEPITAM G Levetiracetam - 250mg 250mg Tablet 700,078 L.L
N03AX14 LEVETIRACETAM ARROW LAB G Levetiracetam - 250mg 250mg Tablet, film coated, breakable 1,243,054 L.L
C10AA07 LIPIROSE OBP 10 G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 575,933 L.L
N03AX14 LEVETIRACETAM BIOGARAN G Levetiracetam - 250mg 250mg Tablet, coated, scored 1,350,562 L.L
L04AX04 LENOMA G Lenalidomide - 10mg 10mg Capsule, hard L.L
A02BC02 LUGANOR G Pantoprazole - 40mg 40mg Injectable lyophilised powder for solution 463,050 L.L
G04BE08 LINK G Tadalafil - 5mg 5mg Tablet, film coated 3,926,708 L.L
N03AX14 LEVIPRAM 250 G Levetiracetam - 250mg 250mg Tablet, film coated 1,087,873 L.L
N06AB04 LECITAL 20 G Citalopram - 20mg 20mg Caplet 1,247,086 L.L
L04AX04 LENOMA G Lenalidomide - 25mg 25mg Capsule, hard L.L
A02BC02 LUGANOR G Pantoprazole - 40mg 40mg Injectable lyophilised powder for solution 4,146,714 L.L
N06AB04 LECITAL 40 G Citalopram - 40mg 40mg Caplet 1,761,778 L.L
L04AX04 LENOMA G Lenalidomide - 15mg 15mg Capsule, hard L.L
J01MA02 LADININ G Ciprofloxacine (lactate) - 200mg/100ml 200mg/100ml Injectable solution 892,591 L.L
N03AX14 LEPITAM G Levetiracetam - 500mg 500mg Tablet 1,100,671 L.L
N03AX14 LEVETIRACETAM ARROW LAB G Levetiracetam - 500mg 500mg Tablet, film coated, breakable 2,441,762 L.L
N03AX14 LEVETIRACETAM BIOGARAN G Levetiracetam - 500mg 500mg Tablet, coated, scored 2,651,401 L.L
A02BC03 LPZ-30 G Lansoprazole - 30mg 30mg Capsule, delayed release 360,150 L.L
A08AB01 LESSFAT G Orlistat - 120mg 120mg Capsule 391,634 L.L
    5
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025